Lightwave Logic, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lightwave Logic, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $236.9K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $95.6K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $40.5K | Mar 18, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2014 | $2.5K | Mar 18, 2016 |
| FY2013 | Dec 31, 2013 | $3.2K | Mar 31, 2014 |
| FY2012 | Dec 31, 2012 | $3.2K | Apr 1, 2013 |
| FY2011 | Dec 31, 2011 | $3.2K | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | $3.2K | Apr 2, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $88.2K | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $38.0K | Mar 18, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.31M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($22.54M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($21.04M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($17.23M) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | ($18.63M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($6.72M) | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | ($6.73M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.77M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($5.75M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($4.41M) | Mar 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.76M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($23.09M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($21.23M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($17.14M) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | ($17.00M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($6.60M) | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | ($6.32M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.60M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($5.52M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($4.14M) | Mar 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.49M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $16.81M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $15.90M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $12.81M | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $12.48M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $4.59M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $4.32M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.79M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $3.52M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $2.47M | Mar 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.75M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($15.55M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($12.24M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($10.53M) | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | ($10.30M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($4.87M) | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | ($4.77M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($4.40M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($4.36M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($3.15M) | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.33M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $2.27M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $3.29M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.31M | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | $1.10M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $158.1K | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $223.5K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.04M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $183.8K | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $129.2K | Mar 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.19M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $37.81M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $41.78M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $29.26M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $27.23M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $7.37M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $6.82M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.45M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $5.85M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $3.19M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.54M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.38M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $5.35M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.71M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.02M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.59M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.92M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $544.5K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $833.1K | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $127.9K | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.65M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $33.42M | Mar 20, 2026 |
| FY2025 | Dec 31, 2023 | $36.43M | Mar 20, 2026 |
| FY2024 | Dec 31, 2022 | $27.55M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $25.20M | Feb 29, 2024 |
| FY2023 | Dec 31, 2020 | $5.78M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $4.91M | Mar 1, 2023 |
| FY2020 | Dec 31, 2018 | $4.91M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $5.02M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $3.06M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($167.31M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($147.00M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2023 | ($124.46M) | Mar 20, 2026 |
| FY2023 | Dec 31, 2022 | ($106.83M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($89.60M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($70.97M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($64.26M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($57.53M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($51.76M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($46.01M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.02M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $27.67M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $31.43M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $24.10M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $23.43M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $3.31M | Mar 1, 2023 |
| FY2022 | Dec 31, 2019 | $2.24M | Mar 1, 2023 |
| FY2020 | Dec 31, 2018 | $2.17M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $3.48M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $1.96M | Mar 18, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 146.05M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 123.30M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | 118.14M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 112.88M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 110.56M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 97.78M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 87.41M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 79.18M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 74.07M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 68.08M | Mar 16, 2018 |